Aurealis Therapeutics

Aurealis Therapeutics is a private biopharmaceutical company. Aurealis Therapeutics is now entering the clinical trial phase with its patented triple-combination product AUP-16: a safe and effective recombinant live biotherapeutic product with a patented active bacterial vector that continuously produces three therapeutic proteins (FGF2, IL4, and CSF1) at the wound site, providing combination biotherapy in a single product. It is intended for the treatment of chronic non-healing wounds and other regenerative conditions. The treatment, based on genetically modified lactic acid bacteria, aims to improve the quality of life for patients requiring tissue generation, such as those with diabetic foot ulcers. For individuals who typically have access only to drugs that treat symptoms rather than promote tissue regeneration itself, this represents a significant advancement.